27 October 2022

Agronomics Limited

("Agronomics" or the "Company")

Director Dealings

Further to the announcement by the Company on 25 April 2022, Agronomics Limited (the "Company") has been notified by Shellbay Investments Limited ("Shellbay") that following expiry of the second vesting period certain of its management and advisory consultants ("Option Holders") have elected to exercise the nil paid options granted by Shellbay in relation to certain shares of the Company held by Shellbay ("Options"). In aggregate, Option Holders have exercised Options over 3,133,074 shares, and the transfer of these shares to relevant Option Holders shall occur with immediate effect. Included in these figures, Mr Denham Eke, a director of the Company, has exercised Options over 213,445 shares held by Shellbay.

Shellbay is a company indirectly wholly owned by Mr James Mellon, a Director of the Company. Mr Denham Eke is also a director of Shellbay.

Following the exercise of Options, Shellbay holds, in aggregate, 12,097,782 Ordinary Shares of the Company, of which 8,278,633 shares remain subject to the Options.

Following the exercise of Options, the interests of the Directors in Ordinary Shares is as set out below:

*Jim Mellon is currently interested in a total of 145,677,122 Ordinary Shares, of which 132,305,380 are held by Galloway Limited and 12,097,782 are held by Shellbay, companies which are both indirectly wholly owned by Jim Mellon, and 1,273,960 Ordinary Shares are held directly by Mr Mellon. Denham Eke is a director of Galloway Limited and Shellbay Investments Limited.

** Richard Reed is currently interested in 6,354,412 Ordinary Shares held by Reepa Limited. Reepa Limited is wholly owned by Richard Reed.

In addition, it is noted for information only that to satisfy current and future tax liabilities relating to the exercise of Options, an advisory company owned by Mr Anthony Chow, a consultant indirectly engaged by Shellbay, sold 3,124,540 Ordinary Shares at a price of 14 pence per share. Accordingly, Mr Chow retains 3,221,752 Ordinary Shares and 6,250,902 Options.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE MARKET ABUSE REGULATION (EU No. 596/2014) AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN AND SUCH PERSONS SHALL THEREFORE CEASE TO BE IN POSSESSION OF INSIDE INFORMATION.

About Agronomics

Agronomics is a leading listed alternative proteins company with a focus on cellular agriculture and cultivated meat. The Company has established a portfolio of 21 companies at the Pre-Seed to Series C stage in this rapidly advancing sector. It seeks to secure minority stakes in companies owning technologies with defensible intellectual property that offer new ways of producing food and materials with a focus on products historically derived from animals. These technologies are driving a major disruption in agriculture, offering solutions to improve sustainability, as well as addressing human health, animal welfare and environmental damage. This disruption will decouple supply chains from the environment and animals, as well as being fundamental to feeding the world's expanding population. A full list of Agronomics' portfolio companies is available at https://agronomics.im/.

About Cellular Agriculture

Cellular Agriculture is the production of agriculture products directly from cells, as opposed to raising an animal for slaughter, or growing crops. This encompasses cell culture to produce cultivated meat and materials, and fermentation processes that harness a combination of molecular biology, synthetic biology, tissue engineering and biotechnology to massively simplify production methods in a sustainable manner.

Over the coming decades, the source of the world's food supply traditionally derived from conventional agriculture is going to change dramatically. We have already witnessed the first wave of this shift with the consumer adoption of plant-based alternative proteins but today, we are on the cusp of an even bigger wave of change. This is being facilitated by advances in cellular agriculture. This change is necessary, given scientists claims that if we maintain existing animal protein consumption patterns, then we will not meet the Paris Agreement's goal of limiting warming to 1.5℃

AT Kearney, a global consultancy firm, projects that cultivated meat's market share will reach 35% by 2040. This combined with the Good Food Institute's estimate that a US$ 1.8 trillion investment will be required in order to produce just 10% of the world's protein using this technology, means that we are on the cusp of a multi-decade flow of capital to build out manufacturing facilities. Funding in the field of cellular agriculture is accelerating, however still less than US$ 2 billion has been invested worldwide since the industry's inception in 2016.

Contacts

For further information please contact: